[{"NetIncomeLoss_1_Q1_USD":-89869000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q1_USD":-3006000.0,"NetIncomeLossAttributableToNoncontrollingInterest_1_Q1_USD":0.0,"ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_1_Q1_USD":0.0,"AccruedLiabilitiesCurrent_0_Q1_USD":78766000.0,"ContractWithCustomerAssetNetCurrent_0_Q1_USD":23397000.0,"OperatingLeaseRightOfUseAssetAmortizationExpense_1_Q1_USD":394000.0,"InterestPaidNet_1_Q1_USD":594000.0,"InventoryFinishedGoods_0_Q1_USD":1906000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-24203000.0,"ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_1_Q1_USD":7760000.0,"IncomeTaxesPaid_1_Q1_USD":2000.0,"Depreciation_1_Q1_USD":3917000.0,"AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":15337000.0,"AssetsCurrent_0_Q1_USD":1989418000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_1_Q1_USD":330051000.0,"SellingGeneralAndAdministrativeExpense_1_Q1_USD":61199000.0,"CostOfGoodsAndServicesSold_1_Q1_USD":2578000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_1_Q1_USD":411907000.0,"CommonStockSharesIssued_0_Q1_shares":140924356.0,"Assets_0_Q1_USD":2248551000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":78856000.0,"GainLossOnInvestments_1_Q1_USD":13000.0,"Liabilities_0_Q1_USD":1567987000.0,"AdditionalPaidInCapitalCommonStock_0_Q1_USD":1925801000.0,"InventoryRawMaterials_0_Q1_USD":18197000.0,"EarningsPerShareBasic_1_Q1_USD":-0.64,"OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_1_Q1_USD":-3006000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":140770000.0,"OtherNonoperatingIncomeExpense_1_Q1_USD":3000.0,"IncomeTaxExpenseBenefit_1_Q1_USD":130000.0,"CommonStockValue_0_Q1_USD":141000.0,"EffectOfExchangeRateOnCashAndCashEquivalents_1_Q1_USD":-126000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThan12MonthsAccumulatedLoss_0_Q1_USD":596000.0,"InvestmentIncomeNet_1_Q1_USD":4643000.0,"StockIssuedDuringPeriodValueShareBasedCompensationGross_1_Q1_USD":7759000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":-7577000.0,"CostsAndExpenses_1_Q1_USD":203578000.0,"ConvertibleDebtCurrent_0_Q1_USD":61816000.0,"OtherAssetsCurrent_0_Q1_USD":123827000.0,"IncreaseDecreaseInInventories_1_Q1_USD":234000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-93001000.0,"IncreaseDecreaseInAccountsPayable_1_Q1_USD":-9569000.0,"AmortizationOfIntangibleAssets_1_Q1_USD":544000.0,"OtherAssetsNoncurrent_0_Q1_USD":49925000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":414155000.0,"ShareBasedCompensation_1_Q1_USD":37861000.0,"IncreaseDecreaseInOtherCurrentLiabilities_1_Q1_USD":-11905000.0,"CommonStockParOrStatedValuePerShare_0_Q1_USD":0.001,"CommonStockSharesAuthorized_0_Q1_shares":300000000.0,"ContractWithCustomerLiabilityRevenueRecognized_1_Q1_USD":26000000.0,"AmortizationOfFinancingCosts_1_Q1_USD":860000.0,"PaymentsRelatedToTaxWithholdingForShareBasedCompensation_1_Q1_USD":15337000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":37861000.0,"AvailableforsaleSecuritiesInUnrealizedLossPositionsQualitativeDisclosureNumberOfPositions1_0_Q1_Investment":414.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-54662000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":140770000.0,"InventoryWorkInProcess_0_Q1_USD":2096000.0,"LiabilitiesCurrent_0_Q1_USD":295105000.0,"AccountsPayableCurrent_0_Q1_USD":9506000.0,"InterestExpense_1_Q1_USD":2414000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":414155000.0,"IncreaseDecreaseInContractWithCustomerAsset_1_Q1_USD":-52807000.0,"AccruedIncomeTaxesCurrent_0_Q1_USD":1326000.0,"OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax_1_Q1_USD":-126000.0,"IncreaseDecreaseInOtherOperatingAssets_1_Q1_USD":-16481000.0,"AvailableForSaleSecuritiesContinuousUnrealizedLossPositionLessThanTwelveMonthsFairValue_0_Q1_USD":435239000.0,"StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_0_Q1_USD":680564000.0,"FiniteLivedIntangibleAssetsNet_0_Q1_USD":28795000.0,"NumberOfOperatingSegments_1_Q1_Segment":2.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":180413000.0,"EarningsPerShareDiluted_1_Q1_USD":-0.64,"IncreaseDecreaseInContractWithCustomerLiability_1_Q1_USD":-23717000.0,"CommonStockSharesOutstanding_0_Q1_shares":140924356.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1221175000.0,"RevenueFromContractWithCustomerExcludingAssessedTax_1_Q1_USD":111607000.0,"OperatingIncomeLoss_1_Q1_USD":-91971000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1_Q1_USD":-89739000.0,"PaymentsToAcquireOtherProductiveAssets_1_Q1_USD":1228000.0,"PaymentsForRepurchaseOfCommonStock_1_Q1_USD":0.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":1405840000.0,"IncreaseDecreaseInAccruedIncomeTaxesPayable_1_Q1_USD":2000.0,"InventoryNet_0_Q1_USD":22199000.0,"ContractWithCustomerLiabilityCurrent_0_Q1_USD":106740000.0,"DeferredIncomeTaxExpenseBenefit_1_Q1_USD":0.0,"LiabilitiesAndStockholdersEquity_0_Q1_USD":2248551000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q1_USD":29263000.0,"IncreaseDecreaseInOtherEmployeeRelatedLiabilities_1_Q1_USD":-36465000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":37861000.0,"ImpairmentOfIntangibleAssetsFinitelived_1_Q1_USD":221000.0,"ProfitLoss_1_Q1_USD":-89869000.0,"StockholdersEquity_0_Q1_USD":680564000.0,"LongTermLoansFromBank_0_Q1_USD":60002000.0,"ContractWithCustomerLiabilityNoncurrent_0_Q1_USD":401966000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":1772000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-4023000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":16491000.0,"ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_1_Q1_USD":-93001000.0,"Ticker":"IONS","CIK":"874015","name":"IONIS PHARMACEUTICALS INC","OfficialName":"Ionis Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"5803570258.0","Country":"United States","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20210505"}]